Home›Blog›Cell Therapy Orchestration: The Vein-to-Vein Guide (2026)
Advanced TherapiesPublished: November 19, 2026Last updated: November 19, 2026

Cell Therapy Orchestration: The Vein-to-Vein Guide (2026)

How scheduling, chain of identity, cold chain and site coordination fit across the CAR-T loop, and where the days are lost.

AC
Anshuman ChaudharyCo-founder & CEO, Zelthy
Share:
Cell Therapy Orchestration, CAR-T vein to vein: cell bags, a vial and a stopwatch on a glowing loop around a patient figure
TL;DR
  • In a two-center CAR-T study, decision-to-vein time (62 days) was almost double vein-to-vein time (32 days), and 30% of referred patients were never treated.
  • A CIBMTR registry analysis linked vein-to-vein time of 40 days or more to worse overall survival with axi-cel (Locke et al., 2025).
  • A typical autologous CAR-T journey has about ten steps owned by different organizations, and one chain-of-identity record has to survive every handoff.
  • FDA removed the REMS for six autologous CAR-T products in June 2025, making community delivery more practical but adding sites and handoffs to coordinate.
  • Orchestration makes delays visible and handoffs reliable; it cannot add manufacturing slots, approve insurance or fix referral gaps.

In a two-center study of 142 patients referred for CAR-T therapy in large B-cell lymphoma, the median time from apheresis to infusion was 32 days, but the median time from treatment decision to infusion was 62 days, and 30% of referred patients never received CAR-T (Hu et al., Transplantation and Cellular Therapy, 2024). Much of that delay happens before any cells are collected. Zelthy, an AI-native platform-as-a-service for life sciences built on the open-source Zango framework, lets pharma and biotech teams configure patient-specific workflows such as apheresis scheduling, chain of custody, cold chain tracking and treatment-center coordination as applications they own. This guide explains what cell therapy orchestration is, where vein-to-vein time is lost, how chain of identity and custody work, and how to evaluate an orchestration platform.

What is cell therapy orchestration?

Cell therapy orchestration is the coordination of every person, system and shipment needed to take a patient's cells (or a donor's cells) from collection to manufacturing and back to the patient as an infused product. It covers scheduling, identity, custody, logistics, site readiness and patient support, with one shared record of status.

The term comes from autologous CAR-T, where the patient is both the source of the starting material and the recipient of the product. A single error in identity is a safety event, and a single missed slot can cost weeks. Orchestration is not one software module. It is the operating model that keeps five coordination layers in step:

  • Scheduling and capacity: apheresis appointments, manufacturing slot allocation, courier pickups, lymphodepletion and infusion dates.
  • Chain of identity (COI): the permanent link between the patient, the collected cells and the finished product.
  • Chain of custody (COC): the record of who held the material, where, when and under what conditions.
  • Logistics and cold chain: fresh or cryopreserved transport, temperature data and excursion handling.
  • Site and patient readiness: referral, financial clearance, caregiver and lodging support, and long-term follow-up.

Data integration runs underneath all five: manufacturer systems (manufacturing execution systems and laboratory information management systems), treatment-center electronic health records, courier tracking and patient support records all have to agree on one status for one patient.

Why vein-to-vein coordination breaks down

Vein-to-vein coordination breaks down because each therapy is a batch of one, built across many organizations that run separate systems, and because time works against the patient. Demand is growing faster than site and manufacturing capacity, so every handoff that slips adds days that some patients cannot afford.

The product base is growing. As of 30 October 2026, the FDA's list of approved cellular and gene therapy products includes seven CAR-T products (Abecma, Aucatzyl, Breyanzi, Carvykti, Kymriah, Tecartus and Yescarta). Globally, the ASGCT and Citeline Q2 2026 report counts 46 approved gene therapies (a figure that includes genetically modified cell therapies) and 76 approved non-modified cell therapies, with 4,487 therapies in development. CAR-T accounts for 66% of the genetically modified cell therapy pipeline in that report.

Time is linked to outcomes. In a CIBMTR registry analysis of commercial axicabtagene ciloleucel patients, first presented at ASH 2022, vein-to-vein time of 40 days or more was associated with a significantly lower complete response rate and worse overall survival than vein-to-vein time under 28 days (hazard ratio 1.33) (Locke et al., Blood Advances, 2025). The same paper's meta-analysis put median vein-to-vein time at 30.6 days for axi-cel, 35.9 days for liso-cel and 48.4 days for tisa-cel. That is an association from observational data, not proof that delay causes worse outcomes.

The longer clock starts before apheresis. In the Hu et al. study, decision-to-vein time (62 days) was almost double vein-to-vein time (32 days). Privately insured patients waited a median 25 days for financial clearance versus 9 days for government-insured patients, and single-case agreements lengthened the wait further (Hu et al., 2024). Among the 43 patients who were referred but never infused, 16 had disease progression or died, and 6 lacked financial clearance.

Two stopwatches: decision to vein 62 days, nearly double vein to vein 32 days, beside a referral clipboard and a cell bag
In one real-world CAR-T cohort, the median wait from treatment decision to infusion (62 days) was almost double the apheresis-to-infusion time (32 days). Source: Hu et al., 2024.

Most eligible patients are never treated. A 2026 review in Transplantation and Cellular Therapy (Shadman et al.) cites stakeholder survey data estimating that about 63% of eligible large B-cell lymphoma patients are not referred to an authorized treatment center and fewer than 2 in 10 (16%) are ultimately treated. The authors list navigation gaps, travel, caregiver requirements, payer delays and brain-to-vein and vein-to-vein times among the barriers.

Manufacturing is not perfectly reliable. In a UK cohort treated at nine centers between 2019 and 2023, 3.9% of patients (38) had at least one failed manufacturing attempt, with bendamustine given within six months of apheresis as a risk factor (Dulobdas et al., Blood Cancer Journal, 2025). Each failure restarts part of the loop: a new collection, a new slot, a new bridging plan.

Sites carry the coordination load. Each manufacturer typically runs its own enrollment and scheduling portal. The Cell and Gene Therapy Consortium, a group of more than 50 organizations, concluded that "a multiplicity of manufacturer portals with varying data requirements and nomenclature is unsustainable" (Mora et al., Transplantation and Cellular Therapy, 2023). The same paper warns that "duplicative data entry increases cybersecurity risk and compromises data integrity," and that patient history should not need to be re-entered into each portal.

The problem is not one slow step. It is a chain of dependent steps owned by different organizations, where the slowest handoff sets the pace.

The vein-to-vein steps: owners, risks and data handoffs

A typical autologous CAR-T journey has about ten steps, and each one changes ownership of either the patient, the material or the data. The table below maps who owns each step, what usually goes wrong and which data must pass to the next owner. Steps vary by product and country.

StepPrimary ownerMain riskData handoff to next step
1. Referral and eligibilityReferring oncologist, authorized treatment centerLate or missed referralReferral packet, diagnosis, prior lines of therapy
2. Financial clearanceTreatment center financial team, payer, manufacturer patient supportAuthorization or single-case agreement delayBenefits verification, authorization status
3. Enrollment and slot bookingTreatment center coordinator, manufacturer scheduling teamNo manufacturing slot in the needed windowEnrollment record, patient identifier, confirmed slot
4. Apheresis collectionApheresis or collection centerLow cell yield, labeling errorCOI identifier, collection record, bag label
5. Inbound transportSpecialty courierMissed pickup, temperature deviationCOC handoff record, temperature log, tracking events
6. Manufacturing and releaseManufacturer (in-house or contract)Manufacturing failure or out-of-specification productBatch status, release decision, expected ship date
7. Outbound cryogenic shipmentSpecialty courierExcursion, dry shipper orientation, customs delayCOC handoff, temperature and orientation data
8. Receipt and storageTreatment center cell therapy lab or pharmacyProduct arrives out of sync with lymphodepletionReceipt verification, COI match, storage location
9. Infusion and early monitoringTreating teamWrong-product administration, toxicityBedside identity check, administration record
10. Long-term follow-upManufacturer, treatment center, registryPatient lost to follow-upFollow-up visits, adverse events, registry data
Table 1. Autologous cell therapy vein-to-vein steps (typical US CAR-T flow)

Table 1. Autologous cell therapy vein-to-vein steps (typical US CAR-T flow)

Two patterns stand out. First, steps 1 to 3 sit before any cells move, which is why decision-to-vein time can exceed vein-to-vein time. Second, steps 4 to 9 all depend on the same identifier surviving every handoff intact, which is the job of chain of identity.

Chain of identity and chain of custody across every handoff

Chain of identity is the permanent link between a patient, their collected cells and the product made from them. Chain of custody is the record of who handled the material, where, when and under what conditions. Together they make sure the right product reaches the right patient, and that every handoff can be audited.

The BioPhorum traceability group describes chain of identity as "the permanent, unequivocal, and transparent association that connects a patient's tissue or cells" to the drug product, and calls traceability "a critical quality attribute for patient safety" (BioPhorum via Bioprocess Online, July 2023). The CGT Consortium paper notes that a single collection typically involves 9 or 10 chain-of-identity and chain-of-custody checks (Mora et al., 2023).

Standards are emerging, not settled. ICCBBA published the ISBT 128 Chain of Identity Identifier standard (ST-028), a globally unique identifier designed to link the donations needed for one cellular therapy product, using requirements developed with the Standards Coordinating Body (SCB). The identifier is meant to be assigned before or at the first collection (ICCBBA, ST-028). In February 2025 the SCB was still surveying organizations on how they implement it, which tells you adoption is uneven. In practice, a single patient can carry a hospital medical record number, an apheresis bag identifier, a manufacturer COI number and a courier tracking number at the same time. GS1 identifiers, familiar from serialization and covered in Zelthy's guide to pharmaceutical traceability, are common in the outbound supply chain, so orchestration systems usually have to map between identifier schemes rather than pick one.

On the regulatory side, FDA's tracking rule for human cells, tissues and cellular and tissue-based products requires that each product be "assigned and labeled with a distinct identification code" and that records allow tracking from donor to consignee and back (21 CFR 1271.290). Which provisions apply to a given product depends on how it is regulated, so sponsors should confirm scope with their regulatory team.

Chain of identity: one COI tag stays with the cells through collect, ship, manufacture and infuse, with a custody check at each step
Chain of identity is one identifier that survives every handoff; chain of custody is the signed record at each link.

What good looks like in operations: identity is verified by scan, not by reading a label aloud; every custody transfer is recorded as an event with time, place and person; and a mismatch stops the process instead of producing a note for later.

Apheresis scheduling, manufacturing slots and treatment-site readiness

Cell therapy scheduling means booking a manufacturing slot, an apheresis appointment, courier pickups and an infusion date that all line up with the patient's clinical status. When capacity is tight, the slot calendar becomes the bottleneck, and the orchestration task is to make capacity visible and allocate it fairly.

The cost of scarce slots became visible after the first BCMA-directed CAR-T launches in myeloma. A survey of US myeloma CAR-T centers led by Mayo Clinic (17 of 20 centers responding) found a median of one manufacturing slot per center per month, a median of 20 patients per center on the waitlist and a median six-month wait before leukapheresis (Kourelis et al., Transplantation and Cellular Therapy, 2023). Capacity has grown since, but slot allocation remains a shared calendar problem between manufacturer and site.

Scheduling has three linked calendars:

  • Manufacturing calendar: slots by product, facility and day, with release dates that depend on QC results.
  • Site calendar: apheresis chairs, cell therapy lab capacity, inpatient or outpatient beds, and staff trained in immune effector cell care.
  • Patient calendar: bridging therapy, washout periods, lymphodepletion timing, caregiver and travel availability.

A change in one calendar must propagate to the other two: if release slips three days, lymphodepletion and the infusion bed move too.

Site requirements changed in 2025. On 26 June 2025, FDA announced it had eliminated the REMS for the six then-approved BCMA- and CD19-directed autologous CAR-T products, so dispensing sites no longer need REMS certification or on-site, immediate access to tocilizumab under a REMS. The updated labeling asks patients to stay near a healthcare facility for at least two weeks and avoid driving for two weeks. Manufacturers still run postmarketing safety studies with 15-year follow-up (AABB, June 2025). For orchestration, shorter lodging periods and fewer certification steps make community and outpatient delivery more practical, which means more sites, more schedules and more handoffs to coordinate. The Shadman et al. review calls the change "likely to improve patient willingness and access," but notes that proximity monitoring still "remains a significant barrier."

Accreditation is moving in the same direction. FACT published standards for immune effector cells in the community clinical setting in November 2025 and has accredited 181 programs for immune effector cell administration since 2017. Each new site is another node to onboard to every manufacturer's process.

A long queue of eligible patients' cell bags waits beside a calendar with only 4 open manufacturing slots
When eligible patients outnumber manufacturing slots, the slot calendar sets the pace of the whole program.

Cell therapy cold chain and courier logistics

Cell therapy cold chain logistics move living material twice: fresh or cryopreserved starting material to the manufacturer, and a cryopreserved product back to the treatment center. Both legs need qualified packaging, continuous temperature data and a defined response when a reading goes out of range.

Fresh cell products are typically shipped at controlled room temperature (15 to 25 C) or refrigerated (2 to 8 C) on a just-in-time basis, while cryopreserved products usually travel in vapor-phase liquid nitrogen dry shippers (Meacle et al., Cell and Gene Therapy Insights, 2016). The same review notes that "the orientation of the dry-shipper is a critical factor impacting the hold time at cryogenic temperatures," and notes that shipments may be monitored with portable temperature recorders whose data the receiving site reads and interprets on arrival.

For orchestration, the questions are about the data around the box:

  • Visibility: is temperature, location and orientation data available during transit, or only when the logger is downloaded at the destination?
  • Exception routing: when an excursion or delay is detected, who is notified, and does the alert reach the manufacturer's quality team and the site at the same time?
  • Disposition: is the product quarantined until quality review, and is that decision linked to the patient's schedule so lymphodepletion is not started on a product that may not be released?
  • Record: does the temperature history attach to the chain-of-custody record for that specific patient?

Predictive excursion detection, where models flag a likely deviation before it happens using lane history, weather and shipper data, is an active area.

Cold chain excursion: a temperature alert on a cryogenic shipper routes the product to quarantine for quality review
The orchestration question is not only whether a shipment stayed cold, but who learns about an excursion and how fast.

Integrating MES, LIMS, EHR, portals and patient support

A cell therapy orchestration platform is only as useful as the systems it connects. It must exchange status with manufacturing and lab systems, treatment-center records, courier networks and patient support teams, so that each party sees one current status without re-keying the same data.

The main integration points are:

  • Manufacturing execution system (MES) and LIMS: batch start, in-process status, QC results, release decision and expected ship date.
  • Treatment-center EHR and cell therapy lab systems: orders, lymphodepletion dates, receipt and administration records. FHIR-based interfaces reduce custom work where the hospital supports them.
  • Courier and packaging data: pickup confirmation, tracking events, temperature and orientation data.
  • Patient support and financial clearance: benefits verification, authorization status, travel and lodging support, and caregiver planning. The Hu et al. data shows that financial clearance alone can take weeks, so this is not a side process. Zelthy's complete guide to patient support programs covers how hub services, financial assistance and case management work, including for cell and gene therapy.
  • Quality and safety: deviations, adverse events and long-term follow-up records.

The site perspective matters most here. The CGT Consortium proposed common data elements for enrollment, ordering and collection, and a universal treatment-center portal framework with "common principles, terminology, and user experiences" (Mora et al., 2023). A manufacturer that adds a new portal without reducing site data entry adds to the problem it was meant to solve. Some therapies also start in early or compassionate access before approval, where the same coordination happens under expanded access pathways.

Integration map: Zelthy hub linking manufacturing, lab, hospital, courier and patient support systems
Orchestration sits between systems that already exist: manufacturing, lab, hospital, courier and patient support.

One status for every patient, across every system?

Zelthy lets cell therapy teams configure scheduling, chain-of-custody event capture, cold chain alerts and treatment-center coordination as applications they own.

See Advanced Therapies →

Autologous, allogeneic and in vivo: how orchestration changes

Autologous therapies need the most orchestration because every batch is made to order for one patient. Allogeneic therapies shift the work toward inventory and distribution, and in vivo CAR-T, still in early trials, could remove apheresis and ex vivo manufacturing from the loop altogether.

An ISPE analysis contrasts the two established models: autologous therapies are a batch of one, made to order, with chain of identity especially critical; allogeneic therapies can supply many patients from one batch, are often made to stock, and depend on donor eligibility, larger cryostorage and wider distribution (Cicalese and Kulkarni, Pharmaceutical Engineering, 2023). For orchestration, autologous programs need slot scheduling and patient-level identity; allogeneic programs look more like specialty distribution with lot-level traceability, order management and patient matching.

In vivo CAR-T is the shift to watch. At ASH 2025, investigators reported first-in-human data for KLN-1010, an in vivo anti-BCMA CAR-T given intravenously without apheresis or lymphodepletion; all four early patients reached MRD negativity within a month (ASCO Post, February 2026). The ASGCT and Citeline Q2 2026 report also tracks in vivo deal activity, including Eli Lilly's acquisition of Kelonia Therapeutics. If in vivo products reach approval, the vein-to-vein loop shortens to a supply chain for a vial, but site readiness, toxicity monitoring and long-term follow-up remain. Orchestration investments should therefore separate what is product-specific (slot scheduling) from what is durable (site coordination, patient support, follow-up, data integration).

Implementation considerations: evaluating, building or buying a platform

Implementing cell therapy orchestration means choosing a delivery route (build, buy or configure on a platform), testing candidates against your own slowest handoffs, and planning integrations and validation early. The evaluation framework below applies to every route.

How to evaluate a cell therapy orchestration platform

Evaluate a cell therapy orchestration platform on whether it shortens the slowest handoffs in your own journey, keeps identity intact without manual workarounds, and reduces work for treatment sites.

CapabilityWhat to askEvidence to requestRed flag
Scheduling and capacityCan manufacturing, site and patient calendars update each other when one changes?Demo of a release delay propagating to lymphodepletion and infusion datesSlot booking by email or spreadsheet behind the portal
Chain of identityHow are identifiers generated, mapped and verified at each handoff?Scan-based verification flow; support for multiple identifier schemes (for example ISBT 128 and GS1)Identity checks recorded as free-text notes
Chain of custodyIs every transfer an event with time, place, person and condition?Audit trail export for one patient journeyCustody data split across courier and manufacturer systems with no join
Cold chain and exceptionsWho is alerted on an excursion or delay, and how is disposition linked to the schedule?Exception workflow with roles, timers and escalationTemperature data only available after delivery
Site experienceHow much data does a site enter, and can it come from the site's own systems?Site user count of fields per enrollment; EHR or FHIR interface optionsAnother login and another form for every product
Patient support and financial clearanceAre benefits verification, travel and lodging support tracked in the same journey?Link between patient support case and treatment scheduleFinancial clearance managed outside the platform with no status feed
Validation and audit readinessDoes it support audit trails, electronic signatures and validation documentation for regulated use?Validation package, change control process, release notesNo documented approach to validated releases
ConfigurabilityCan new products, sites and countries be added by configuration rather than custom builds?Time and effort for the last new-site or new-product rolloutEach new product requires a new project
Data ownership and exitWho owns the data and the application logic, and how would you move it?Contract terms, export formats, code accessData or workflows locked in a proprietary format
Table 2. Capability evaluation framework for a cell therapy orchestration platform (vendor-neutral)

Table 2. Capability evaluation framework for a cell therapy orchestration platform (vendor-neutral)

Build, buy or platform

Sponsors usually choose between building in-house, buying a packaged orchestration product, or configuring applications on a development platform. The right choice depends on how many products and sites you run, how different your processes are, and how much control you need over data and change.

  • Build: full control, but the team must also own hosting, security, validation and every integration. It fits sponsors with strong engineering teams and stable processes.
  • Buy a packaged product: faster to a standard workflow, but differences in your process may need workarounds, and the data model belongs to the vendor.
  • Platform: configure workflows on shared building blocks (identity, workflow, permissions, audit, integration) and keep the application. Zelthy takes this approach: teams can configure scheduling, chain-of-custody event capture, cold chain tracking with excursion alerts, treatment-center coordination and long-term follow-up on Zelthy, built on the open-source Zango framework with multi-tenant architecture, HIPAA and GDPR controls and FHIR interoperability. Customers keep ownership of the code, so there is no lock-in to one vendor's data model. The Zelthy Advanced Therapies solution outlines these use cases.

Whatever the route, four practical points decide the timeline:

  1. Map the journey first. Document each handoff using a structure like Table 1, including the identifiers each party uses today. Most surprises come from undocumented manual steps.
  2. Integrate the slowest handoffs first. If financial clearance or slot booking drives delay, start there, not with dashboards.
  3. Plan validation from day one. Orchestration records support GxP decisions, so requirements, risk assessment, testing and change control should be planned with quality, not added before go-live.
  4. Design for the site. Test enrollment and scheduling flows with coordinators at two or three treatment centers before scaling.

What orchestration cannot fix

Orchestration software makes delays visible and handoffs reliable, but it cannot create manufacturing capacity, approve insurance or change biology. Being clear about those limits points investment where it matters.

  • Capacity: a platform can show the slot queue and allocate it by agreed rules. It cannot add a slot that does not exist.
  • Payers: it can track authorization status and prompt follow-up. Payer decision times, single-case agreements and coverage policy sit outside the software.
  • Manufacturing outcomes: it can trigger re-collection workflows quickly. It cannot prevent failures linked to the patient's prior treatment or cell quality.
  • Referral: if 63% of eligible patients are never referred, the bottleneck is upstream of any treatment-center workflow. Education and community partnerships matter more there.
  • Standards: until identifier and data standards are widely adopted, any platform will spend effort mapping between schemes.
  • Adoption: a well-designed system that sites do not use is another portal. Site burden has to be measured, not assumed.
  • AI predictions: excursion or delay predictions are only as good as the data behind them, and should support people, not make release decisions.

Case evidence: what Zelthy can and cannot show today

No advanced-therapy outcome metric for a program deployed on Zelthy has been approved for publication, so this guide does not claim one. The evidence available is platform scale and results from adjacent, patient-specific workflows.

Across deployments, Zelthy has supported programs reaching more than 1 million patients in 12+ countries, with 300+ applications deployed on the platform. Roche, Bristol-Myers Squibb, AstraZeneca and Novo Nordisk are among Zelthy's clients, though not necessarily for cell therapy work.

The closest analog is a compassionate access program deployed on Zelthy, which reported 65% faster approvals and 40% lower operational costs, and was deployed in 5 weeks. It shares several traits with cell therapy: patient-specific approvals, regulated documentation and multi-party coordination. It does not involve apheresis, manufacturing slots or cryogenic logistics, so the results should be read as evidence of how quickly regulated, patient-level workflows can be configured on the platform, not as a cell therapy outcome. On the solution side, the Zelthy Advanced Therapies page describes the cell and gene therapy orchestration use cases in more detail.

Frequently asked questions

What is cell therapy orchestration?

Cell therapy orchestration is the coordination of scheduling, chain of identity, chain of custody, logistics, site readiness and patient support needed to take a patient's cells from collection to manufacturing and back to infusion. It gives every party one shared, current status for each patient.

What is vein-to-vein time in CAR-T therapy?

Vein-to-vein time is the interval from apheresis (cell collection) to infusion of the finished product. A 2025 meta-analysis reported medians of about 31 to 48 days across the approved CD19 CAR-T products, and a 2024 two-center study reported 32 days, with decision-to-infusion time of 62 days.

What is the difference between chain of identity and chain of custody?

Chain of identity is the permanent link between a patient, their collected cells and the finished product. Chain of custody is the record of who handled the material, where, when and under what conditions. Both are needed so the right product reaches the right patient and every handoff can be audited.

Do CAR-T therapies still require a REMS?

On 26 June 2025, FDA eliminated the REMS for the six then-approved BCMA- and CD19-directed autologous CAR-T products. Updated labeling asks patients to stay near a healthcare facility for at least two weeks and avoid driving for two weeks, and postmarketing safety studies continue.

Why does CAR-T take so long to reach patients?

Delays come from referral, financial clearance, manufacturing slot availability, manufacturing time and occasional manufacturing failures. In one real-world study, the time from treatment decision to infusion was almost double the time from apheresis to infusion, showing that much of the delay happens before cells are collected.

Will in vivo CAR-T remove the need for orchestration?

In vivo CAR-T could remove apheresis and ex vivo manufacturing, but it is still in early trials. Site readiness, toxicity monitoring, patient support and long-term follow-up would still need coordination, so orchestration would change shape rather than disappear.

If you are planning or scaling a cell therapy program and want to see how vein-to-vein workflows can be configured on a platform you own, book a demo with the Zelthy team.

This article is for general information and is not legal or regulatory advice. Confirm product-specific requirements with your regulatory team.

Sources

Approved Cellular and Gene Therapy Products. U.S. Food and Drug Administration. Content current as of 30 Oct 2026.

FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous CAR T Cell Immunotherapies. U.S. Food and Drug Administration. 26 Jun 2025.

FDA Eliminates REMS for Approved CAR T-Cell Therapies. AABB. 30 Jun 2025.

Gene, Cell, and RNA Therapy Quarterly Data Report, Q2 2026. ASGCT and Citeline. Jul 2026.

Hu B, Vaidya R, Ahmed F, et al. Real-World Analysis of Barriers to Timely Administration of CAR T Cell Therapy in Diffuse Large B-cell Lymphoma. Transplantation and Cellular Therapy. 2024;30(11).

Locke FL, Siddiqi T, Jacobson CA, et al. Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel. Blood Advances. 2025;9(11):2663-2676.

Shadman M, Ahlstrom J, Gutierrez M, et al. Barriers to Patient Referral and Completion of CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma. Transplantation and Cellular Therapy. 2026.

Mora A, Barnes L, Divine C, et al. The Cell and Gene Therapy Consortium's Perspective on Harmonizing Data Collection for Patient Enrollment, Therapy Ordering and Scheduling, and Cell Collection. Transplantation and Cellular Therapy. 2023;29(11):653-665.

Dulobdas V, Kirkwood AA, Serpenti F, et al. Risk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: a report from the UK National CAR T Panel. Blood Cancer Journal. 2025;15(1):30.

Kourelis T, Bansal R, Berdeja J, et al. Ethical Challenges with Multiple Myeloma BCMA Chimeric Antigen Receptor T Cell Slot Allocation: A Multi-Institution Experience. Transplantation and Cellular Therapy. 2023;29(4):255-258.

ST-028 Chain of Identity Identifier. ICCBBA.

SCB Conducting Survey on ICCBBA Chain of Identity Standard. AABB. 26 Feb 2025.

A Practical Proposal for Standardizing Traceability of Cell and Gene Therapies. BioPhorum via Bioprocess Online. 21 Jul 2023.

21 CFR 1271.290 Tracking. eCFR.

FACT's New Standards for Immune Effector Cells in the Community Clinical Setting. Foundation for the Accreditation of Cellular Therapy. 10 Nov 2025.

Meacle F, Salkin J, Brice M, Harris I. Key Considerations of Cell and Gene Therapy Cold Chain Logistics. Cell and Gene Therapy Insights. 2016.

Cicalese P, Kulkarni N. Delivering Curative Therapies: Autologous vs. Allogeneic Supply Chains. ISPE Pharmaceutical Engineering. Nov/Dec 2023.

Early Findings From First Human Study of In Vivo CAR T in Myeloma. The ASCO Post. 25 Feb 2026.

Related Solution

Planning or scaling a cell therapy program?

Zelthy is pharma's advanced therapies platform — configure vein-to-vein workflows such as apheresis scheduling, chain of custody, cold chain tracking and treatment-center coordination on the open-source Zango framework, keep ownership of the code, and build on a platform that has supported programs reaching more than 1 million patients in 12+ countries.

See the Advanced Therapies Solution →

Similar Blogs